United Therapeutics heads into its October 28 earnings with a pointed new sell rating from Goldman Sachs, short interest climbing sharply, and options traders rotating toward hedges, a convergence of cautious signals around a stock that has already slipped 6.6% over the past month.
The most headline-grabbing development arrived six days ago. Goldman Sachs initiated coverage with a Sell rating and a $321 price target, a call that lands 33% below the current price of $481.47 and sits well below the consensus mean target of $637.92. That gap between Goldman's bearish entry point and where most of the Street is positioned tells the story: the existing bulls at RBC Capital (Outperform, $677), JP Morgan (Overweight, $687) and Wells Fargo (Overweight, $738) have not moved, but Goldman's initiation has introduced a material dissenting voice that the market appears to be digesting. The consensus rating has flipped to Sell, though with just one Sell against multiple Outperform and Overweight ratings, that label may overstate the bearish weight on the Street. The bull case centres on United Therapeutics' dominant position in the prostacyclin pathway for pulmonary arterial hypertension and the pipeline of new indications including IPF and PH-ILD. Goldman's bear case, consistent with existing concerns, points to uncertainty around Tyvaso's antifibrotic activity in IPF and competition risk in that broader market.
Short positioning has moved meaningfully in the same direction as Goldman's call. Short interest in UTHR has risen 13.9% over the past week to 6.2% of the free float, roughly 2.67 million shares. That is a notable step-up: for most of August and early September, short interest ran below 2.2 million shares. The jump appears to have started around September 21, with reported shares short rising from roughly 2.17 million to over 2.7 million in three sessions. At the same time, borrowing conditions remain entirely undemanding. Cost to borrow has fallen 20% on the week to just 0.27%, the lowest level in the 30-day history visible in the data. Availability is extremely loose at 3,397%, meaning the lending pool holds roughly 34 times more shares available to borrow than are currently shorted. A short interest build under these conditions is not a squeeze setup. New shorts can enter freely at negligible cost, and there is no mechanical pressure to cover.
Options positioning has also shifted toward caution since mid-September. The put/call ratio is running at 0.94, above its 20-day average of 0.82 and about one standard deviation elevated, after spending most of August and early September below 0.75. The move is not extreme, the 52-week high reached 1.82, but the direction of travel has been consistent for two weeks. That mild defensive tilt in options aligns with the short interest build: the market is hedging rather than expressing a high-conviction bearish view. Valuation has also drifted lower, with the price-to-earnings multiple contracting by about 1.1 points over the past 30 days to 16.4x, and price-to-book down 0.16 points. Neither move is dramatic, but both reflect a stock where the re-rating has been modest and gradual rather than a sharp dislocation.
One real-economy data point adds texture without offering a forecast. The Centers for Medicare and Medicaid Services Medicaid drug utilisation data shows that Medicaid prescriptions for United Therapeutics have fallen for three consecutive quarters, with the most recent reading at 5,208 prescriptions for the period ending January 2026. Medicaid dollars reimbursed came in 11% below the same quarter a year earlier at $75.7 million. Neither dataset has been measured by ORTEX to lead the company's reported revenue figures, so these are sector-level observations rather than indicators, but a three-quarter declining streak in Medicaid prescription volumes is a factual backdrop worth noting as the company approaches its October 28 print.
Founder and CEO Martine Rothblatt filed several open-market sales on September 28, with net proceeds totalling around $1.9 million across multiple tranches, all conducted under a pre-arranged 10b5-1 plan. Because the trades were pre-scheduled, they carry limited signal about near-term conviction. Rothblatt remains a significant holder with 668,728 shares on the register. Wellington Management filed an amended 13G in August disclosing a reduction to 3.2% of the class from 5.7%, a material trim that is now on record, though as-last-disclosed figures around the 5% threshold can lag actual positioning.
With earnings 28 days away, the question is whether Goldman's Sell initiation draws further analyst attention or remains an outlier against a broadly constructive consensus. The October 28 print will be the first opportunity to test whether the short interest build and options hedging that emerged this week reflect a genuine shift in the fundamental narrative or simply event-driven caution ahead of a quarter.
See the live data behind this article on ORTEX.
Open UTHR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
